Among all evaluable patients who received pembrolizumab/lenvatinib, the ORR was 50.6% (95% CI, 42.6%-58.7%), a DCR of 82.3% (95% CI, 75.4%-87.9%), and a CBR of 71.5% (95% CI, 63.8%-78.4%). #kicsm #KCRS2025 | @kidneycan @AlbigesL https://t.co/dMgRozzFha

Thanks #ASCO25 for the amazing opportunity to present some of the @GustaveRoussy works @FAndreMD @barlesi @drcmassard @BenjaminBesseMD @dplanchard @BarbaraPistill2 @EmelineColomba @JordiRemon @HollebecqueA @Ribeiro2M @MichelsJudith @derosa__lisa and many more !

🎉 Excited to share that @derosa_lisa will be the Keynote Speaker at 2025 IKCS: Europe! #IKCSEU25 Don't miss her talk on the kidney cancer #microbiome. Register with discount rates till 4/10! https://t.co/UAzsbVfCxE

Day 1 @myESMO #Preceptorship in Metastatic #urothelial #RCC #cancer 62 participants from 26 countries selected out of >230 applicants ! Thanks to the faculty for sharing #SOC @myESMO #guidelines

In his Keynote Lecture at #ELCC25, @BenjaminBesseMD discusses when ‘less is more,’ describing different de-escalation strategies to balance the efficacy versus toxicity of #CancerTreatment, particularly #immunotherapy Read more in the #ESMODailyReporter🔗 https://t.co/QIDDrx5g3d

Today is a very special day for patients with RCC : CHMP as approved BELZUTIFAN both for VHL disease associated RCC and for advanced renal cell carcinomas (following CPI and 2 VEGFR TKIs) Data presented at @myESMO and published in @NEJM

Please join @AlbigesL @g_develasco #JensBedkeMD & myself at #ESMO24 for a discussion of #kidneycancer that will span topics of #adjuvant & #metastatic dz tx. We have worked hard to incorporate discussion around data presented just a day earlier- incl perspectives on #TiNivo2,

#BreakingNews‌ Our 2023 IF is now 8.3 ! So proud of our amazing team @AlbigesL @UroDocAsh @Ric_Campi @Ecastromarcos @jteoh_hk @CaPsurvivorship @RenuEapen @GPloussard @CathyJPierce @EurUrolOncol

KIM-1 is a novel prognostic and predictive biomarker in the adjuvant RCC space. Great data at #ASCO24 and stellar discussion by @VincentWenxinXu (Academy of Kidney Cancer Investigators member!). We discuss the KIM-1 data with @AlbigesL https://t.co/bDsGpwGlFG

Circulating kidney injury molecule-1 may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma. #ASCO24 #kcsm @AlbigesL https://t.co/fh4uQlCJBH

Exciting preliminary data from Phase I/Ib study of HIF2α inhibitor DFF332 in pts w/ advanced ccRCC presented by my dear friend @montypal at #ASCO24: promising safety profile, indications of clinical activity, and dose-proportional modulation of EPO. @ASCO @AlbigesL @OncoAlert

Top 5 Must See Kidney and Bladder Data @montypal #ASCO24 @ASCO @AlbigesL @brian_rini @motzermd @shilpaonc @CityofHope_GU @cityofhope Click Here for the Data Links: https://t.co/0RUwnXQw7M

Don't miss tomorrow's Rapid Oral Abstract Session - Friday 8:30 @Montypal will present the Preliminary results of P1 study monotherapy of DFF332: promising safety profile & have been indications of clinical activity @ASCO #ASCO24 @AlbigesL 👉 https://t.co/RIZevrilHu

Renal cancer highlights #ASCO24 KIM1 biomarker data (blood) stands out. KIM1 (TIM1-4 family) ⬆️ in kidney injury and is immune suppressive(Treg), Already used for nephrotox. @motzermd presented compelling data form adjuvant ipi/nivo #AACR24. A 2nd +ve study would be meaningful?

Updated 📢#RenalCellCarcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Assessing mature data for first-line metastatic trials as well as sequencing strategies & new agents such as belzutifan. https://t.co/tpp9TnN7tz #kcsm @silke_gillessen

#ASCO24 abstracts titles are out!!!! https://t.co/NejATQFBpq My top 5 communications in Kidney & Bladder based on the titles: 1. Avelumab + axitinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC): Final overall survival (OS) analysis from the JAVELIN

Still time to apply 👉 #ESMOPreceptorship on Metastatic #BladderCancer & #KidneyCancer: molecular pathology & diagnosis as contributing factors to heterogeneity, assessment & multidisciplinary tx, advances in tx & novel targets 🔗 https://t.co/34w6U4ogVf #blcsm #kcsm @AlbigesL

Proud of @GustaveRoussy GU group celebrating 20th anniversary #GU24 🎂 Thrilled to contribute to 20years of advances in GU cancers care ! Missing @PBlanchardMD @AlbertoBossial @drcmassard

The #MCCRWorkshop enables peer #mentoring and #CareerDevelopment for early-career #oncology professionals. Apply now to gain access to mentors and develop protocols ready for submission. ⏲️ Deadline: 1 February 2024. https://t.co/zX9bPZMGTO @EORTC @AACR #CancerResearch

Listening to "December 2023 – Eur Urol Oncology highlights" at https://t.co/9aYA4icaBR @EurUrolOncol @Uroweb @UroDocAsh @Ric_Campi @CathyJPierce @Ecastromarcos @CaPsurvivorship @GPloussard @jteoh_hk @AlbigesL @declangmurphy